EA200700055A1 - Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением - Google Patents

Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением

Info

Publication number
EA200700055A1
EA200700055A1 EA200700055A EA200700055A EA200700055A1 EA 200700055 A1 EA200700055 A1 EA 200700055A1 EA 200700055 A EA200700055 A EA 200700055A EA 200700055 A EA200700055 A EA 200700055A EA 200700055 A1 EA200700055 A1 EA 200700055A1
Authority
EA
Eurasian Patent Office
Prior art keywords
forms
memantine
preparative
formal
oral
Prior art date
Application number
EA200700055A
Other languages
English (en)
Other versions
EA011290B1 (ru
Inventor
Ян Янг
Раджив Джанджикхел
Нираньян Рао
Антонио Периклоу
Ваттанапорн Абрамовитц
Махендра Г. Дедихия
Эрхард Зайллер
Бернхард Хауптмайер
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200700055A1 publication Critical patent/EA200700055A1/ru
Publication of EA011290B1 publication Critical patent/EA011290B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к твердой пероральной лекарственной форме с немедленным высвобождением, содержащей 1-аминоциклогексаны, предпочтительно мемантин или нерамексан, и необязательно фармацевтически приемлемое покрытие, где активный ингредиент проявляет пропорциональность дозы и высвобождается со скоростью растворения более приблизительно 80% в пределах первых приблизительно 60 мин после поступления указанной формы в среду применения. Лекарственная форма подвергается прямому прессованию и имеет твердость от приблизительно 3 до приблизительно 40 Kр, показывает среднее Tот приблизительно 2 до приблизительно 8 ч с нагрузкой активного ингредиента от приблизительно 2,5 до приблизительно 150 мг. Препаративная форма позволяет создавать композиции с пропорциональными дозами для приема один или два раза в день, а также поддерживать устойчивый средний диапазон T.
EA200700055A 2004-06-17 2005-06-16 Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением EA011290B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58124404P 2004-06-17 2004-06-17
PCT/US2005/021284 WO2006096194A2 (en) 2004-06-17 2005-06-16 Drinkable immediate release tablet made with direct compression of memantine or neramexane

Publications (2)

Publication Number Publication Date
EA200700055A1 true EA200700055A1 (ru) 2007-10-26
EA011290B1 EA011290B1 (ru) 2009-02-27

Family

ID=36953777

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700055A EA011290B1 (ru) 2004-06-17 2005-06-16 Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением

Country Status (11)

Country Link
EP (3) EP2601937A1 (ru)
JP (1) JP5025468B2 (ru)
KR (1) KR20090033410A (ru)
CN (1) CN101389315A (ru)
AU (1) AU2005328701B2 (ru)
BR (1) BRPI0512263A (ru)
CA (1) CA2568445C (ru)
EA (1) EA011290B1 (ru)
ES (1) ES2483126T3 (ru)
IL (1) IL179992A (ru)
WO (1) WO2006096194A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498450B2 (en) 2007-09-12 2016-11-22 Merz Pharma Gmbh & Co. Kgaa 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus
ES2416071T3 (es) * 2009-06-29 2013-07-30 Merz Pharma Gmbh & Co. Kgaa Método para preparar 1-amino-1,3,3,5,5-pentametilciclohexano
WO2011000538A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
CA2765609A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
EP2316434A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of memantine
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
EP2585049A1 (en) * 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
CN103347506A (zh) 2010-10-12 2013-10-09 约翰.霍普金斯大学 包含美金刚的镇咳组合物
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
EP2526925A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi A dose adjustable oral pump spray or aerosol spray containing memantine
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
CN114199812A (zh) * 2021-12-28 2022-03-18 南通联亚药业有限公司 一种盐酸美金刚缓释制剂中盐酸美金刚的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA974518A (en) 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
EP0581856B1 (en) 1991-04-19 1999-07-14 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IL133235A (en) 1997-06-30 2004-02-19 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
CN1642547A (zh) * 2002-01-16 2005-07-20 恩多制药公司 治疗中枢神经系统障碍的药物组合物和方法
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
WO2004112768A1 (en) * 2003-06-16 2004-12-29 Allergan, Inc. Memantine oral dosage forms
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
ES2332920T3 (es) * 2004-01-20 2010-02-15 Novartis Ag Proceso y formulacion de compresion directa.
AU2005209310B2 (en) * 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso

Also Published As

Publication number Publication date
EP1765287A2 (en) 2007-03-28
CA2568445A1 (en) 2006-09-14
ES2483126T3 (es) 2014-08-05
JP5025468B2 (ja) 2012-09-12
EP2397122A3 (en) 2012-01-25
EP2397122B1 (en) 2014-05-14
JP2008509089A (ja) 2008-03-27
IL179992A (en) 2012-02-29
AU2005328701A1 (en) 2006-09-14
WO2006096194A8 (en) 2007-01-11
KR20090033410A (ko) 2009-04-02
BRPI0512263A (pt) 2008-02-26
CN101389315A (zh) 2009-03-18
WO2006096194A2 (en) 2006-09-14
IL179992A0 (en) 2007-05-15
EA011290B1 (ru) 2009-02-27
EP2601937A1 (en) 2013-06-12
CA2568445C (en) 2011-05-24
EP2397122A2 (en) 2011-12-21
AU2005328701B2 (en) 2009-08-13
WO2006096194A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EA200700055A1 (ru) Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
MY148773A (en) Galenic formulations of organic compounds
JP2008543936A5 (ru)
RU2011133242A (ru) Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции
EA200400471A1 (ru) Оральная дозированная форма пропиверина
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
GEP20094627B (en) High drug load tablet
SV2008002612A (es) Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MY151470A (en) Controlled release solid preparation
RU2012125827A (ru) Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
SI1843754T1 (sl) Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
DK1653923T3 (da) Oral afleveringssystem omfattende en bivæsket skum
MA32722B1 (fr) Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion
RU2009145804A (ru) Аксомадол для лечения боли от артроза
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU